← FDA DRUG APPROVALS

FDA NDA · NDA018614

LIPOSYN 20%

Sponsor: ABBOTT

APPLICATION
NDA018614
TYPE
NDA
ORIGINAL APPROVAL
1981-10-26
LATEST ACTION
1996-04-26
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

LIPOSYN 20%Discontinued
SAFFLOWER OIL 20% (20GM/100ML) · INJECTABLE · INJECTION

Approval history

1996-04-26Labeling · Supplement 7AP
1984-08-10Labeling · Supplement 11AP
1984-02-27Labeling · Supplement 9AP
1982-10-22Labeling · Supplement 6AP
1982-04-20Labeling · Supplement 2AP
1982-03-08Labeling · Supplement 3AP
1981-10-26Type 3 - New Dosage Form · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →